JP7492757B2 - 遺伝子の発現制御剤、アルツハイマー病の予防薬または治療薬および認知症の改善方法 - Google Patents

遺伝子の発現制御剤、アルツハイマー病の予防薬または治療薬および認知症の改善方法 Download PDF

Info

Publication number
JP7492757B2
JP7492757B2 JP2022044972A JP2022044972A JP7492757B2 JP 7492757 B2 JP7492757 B2 JP 7492757B2 JP 2022044972 A JP2022044972 A JP 2022044972A JP 2022044972 A JP2022044972 A JP 2022044972A JP 7492757 B2 JP7492757 B2 JP 7492757B2
Authority
JP
Japan
Prior art keywords
hsa
mir
stem cells
microparticles
dental pulp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022044972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023139438A (ja
JP2023139438A5 (https=
Inventor
祥嗣 古賀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dexon Pharmaceuticals Inc
Original Assignee
Dexon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dexon Pharmaceuticals Inc filed Critical Dexon Pharmaceuticals Inc
Priority to JP2022044972A priority Critical patent/JP7492757B2/ja
Priority to CN202380027002.7A priority patent/CN119031942A/zh
Priority to US18/848,758 priority patent/US20250195554A1/en
Priority to PCT/JP2023/010775 priority patent/WO2023182243A1/ja
Priority to EP23774838.9A priority patent/EP4497445A1/en
Publication of JP2023139438A publication Critical patent/JP2023139438A/ja
Publication of JP2023139438A5 publication Critical patent/JP2023139438A5/ja
Application granted granted Critical
Publication of JP7492757B2 publication Critical patent/JP7492757B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022044972A 2022-03-22 2022-03-22 遺伝子の発現制御剤、アルツハイマー病の予防薬または治療薬および認知症の改善方法 Active JP7492757B2 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2022044972A JP7492757B2 (ja) 2022-03-22 2022-03-22 遺伝子の発現制御剤、アルツハイマー病の予防薬または治療薬および認知症の改善方法
CN202380027002.7A CN119031942A (zh) 2022-03-22 2023-03-19 基因表达调控剂、阿尔茨海默症的预防药或治疗药和痴呆的改善方法
US18/848,758 US20250195554A1 (en) 2022-03-22 2023-03-19 Gene expression regulator, agent for preventing or treating alzheimer's disease and method for improving dementia
PCT/JP2023/010775 WO2023182243A1 (ja) 2022-03-22 2023-03-19 遺伝子の発現制御剤、アルツハイマー病の予防薬または治療薬および認知症の改善方法
EP23774838.9A EP4497445A1 (en) 2022-03-22 2023-03-19 Gene expression regulator, prophylactic drug or therapeutic drug for alzheimer's disease, and method for improving dementia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2022044972A JP7492757B2 (ja) 2022-03-22 2022-03-22 遺伝子の発現制御剤、アルツハイマー病の予防薬または治療薬および認知症の改善方法

Publications (3)

Publication Number Publication Date
JP2023139438A JP2023139438A (ja) 2023-10-04
JP2023139438A5 JP2023139438A5 (https=) 2023-11-14
JP7492757B2 true JP7492757B2 (ja) 2024-05-30

Family

ID=88100891

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022044972A Active JP7492757B2 (ja) 2022-03-22 2022-03-22 遺伝子の発現制御剤、アルツハイマー病の予防薬または治療薬および認知症の改善方法

Country Status (5)

Country Link
US (1) US20250195554A1 (https=)
EP (1) EP4497445A1 (https=)
JP (1) JP7492757B2 (https=)
CN (1) CN119031942A (https=)
WO (1) WO2023182243A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2025170079A1 (https=) * 2024-02-09 2025-08-14
CN118236389B (zh) * 2024-05-28 2024-09-24 南京晖丽生物科技有限公司 miR-3120在制备预防及治疗肿瘤及肿瘤恶液质的药物组合物中的应用
CN119185350B (zh) * 2024-08-15 2025-09-09 安徽农业大学 靶向lrp6的抑制剂在调节动物剩余采食量中的应用
CN119193819B (zh) * 2024-11-28 2025-05-13 苏州麦锐克生物科技有限公司 用于阿尔茨海默病诊断的多重miRNA标志物及试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021520790A (ja) 2018-04-10 2021-08-26 ブレインストーム セル セラペウティクス リミテッド 細胞型特異的エキソソームおよびそれらの使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2011118795A1 (ja) 2010-03-26 2013-07-04 国立大学法人名古屋大学 損傷部治療用組成物
JP2017184642A (ja) 2016-04-01 2017-10-12 株式会社ヘルシーパス 認知症マーカー、それを用いた認知症の評価方法、評価試薬および評価キット
JP2018023343A (ja) 2016-08-12 2018-02-15 国立大学法人山口大学 細胞培養用培地、及び細胞培養方法
IL264825B (en) 2016-08-14 2022-08-01 Univ Ramot Mesenchymal cell-derived exosomes to treat neurological disorders
AU2020299633B2 (en) * 2019-07-02 2026-03-26 Ohio State Innovation Foundation Neurodegenerative disease therapies utilizing the skin-brain axis
US20210002650A1 (en) * 2019-07-03 2021-01-07 University Of Virginia Patent Foundation Compositions and methods for treating alzheimer's disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021520790A (ja) 2018-04-10 2021-08-26 ブレインストーム セル セラペウティクス リミテッド 細胞型特異的エキソソームおよびそれらの使用

Also Published As

Publication number Publication date
JP2023139438A (ja) 2023-10-04
WO2023182243A1 (ja) 2023-09-28
CN119031942A (zh) 2024-11-26
US20250195554A1 (en) 2025-06-19
EP4497445A1 (en) 2025-01-29

Similar Documents

Publication Publication Date Title
JP7492757B2 (ja) 遺伝子の発現制御剤、アルツハイマー病の予防薬または治療薬および認知症の改善方法
JP6894652B1 (ja) 組織修復剤、組織修復剤の使用方法およびスクリーニング方法
US20240424029A1 (en) Agent for improving cancer cachexia and method for improving cancer cachexia
US20260103713A1 (en) Microparticle, agent for activating nk cell, method for culturing nk cell, method for producing activated nk cell, and method for activating nk cell
CN116171158A (zh) 细胞因子风暴抑制剂、细胞因子风暴抑制剂的使用方法和筛选方法
WO2023190267A1 (ja) 微小粒子、パーキンソン病の予防薬または治療薬およびパーキンソン病の改善方法
JP2024000505A (ja) Ｐｔｘ３の発現制御剤；関節リウマチ、自己免疫疾患に伴う血管炎または皮膚硬化の予防薬または治療薬、あるいはそれらの改善方法
JP2025032034A (ja) 若返り剤および若返り方法
WO2023199828A1 (ja) 微小粒子、血管新生眼疾患の予防薬または治療薬および血管新生眼疾患の改善方法
JP7720630B2 (ja) 微小粒子、勃起不全の予防薬または治療薬および勃起不全の改善方法
JP2025172276A (ja) 遺伝子の発現制御剤、アルツハイマー病の予防薬または治療薬および認知症の改善方法
US20250382614A1 (en) Hmgb1 expression regulator, prophylactic agent or therapeutic agent for acute lung injury, acute respiratory distress syndrome, or sepsis, or method of ameliorating same
WO2023199829A1 (ja) 微小粒子、うつ病の予防薬または治療薬およびうつ病の改善方法
WO2023248845A1 (ja) Ｐｔｘ３の発現制御剤；関節リウマチ、自己免疫疾患に伴う血管炎または皮膚硬化の予防薬または治療薬、あるいはそれらの改善方法
JP2025095535A (ja) Ｐｔｘ３の発現制御剤；関節リウマチ、自己免疫疾患に伴う血管炎または皮膚硬化の予防薬または治療薬、あるいはそれらの改善方法

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20220509

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231103

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231103

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231103

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240319

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240508

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240513

R150 Certificate of patent or registration of utility model

Ref document number: 7492757

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150